Aditya Venugopal

Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.